<sup>18</sup>F-FDG PET/CT在ⅠA期非小细胞肺癌患者诊疗中的研究进展

张鹏; 姚稚明; 张鹏; 姚稚明

doi:10.3760/cma.j.cn121381-202201016-00232

[1]

Jacobs CD, Jafari ME. Early results of lung cancer screening and radiation dose assessment by low-dose CT at a community hospital[J]. Clin Lung CancerClin Lung Cancer, 2017, 18(5): e327-e331. doi: 10.1016/j.cllc.2017.01.011

[2]

陈英, 钟文昭. 第8版肺癌TNM分期浅析[J]. 临床外科杂志, 2016, 24(7): 486-490. doi: 10.3969/j.issn.1005-6483.2016.07.002
Chen Y, Zhong WZ. Analysis of TNM staging of lung cancer in the 8th edition[J]. J Clin SurgJ Clin Surg, 2016, 24(7): 486-490. doi: 10.3969/j.issn.1005-6483.2016.07.002

[3]

Ye L, Xu F, Shi S, et al. A SUV_max-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage Ⅰ non-small cell lung cancer: unveiling the role of ¹⁸F-FDG PET/CT in clinical decision-making[J]. Clin Transl OncolClin Transl Oncol, 2018, 20(8): 1026-1034. doi: 10.1007/s12094-017-1819-7

[4]

Tsutani Y, Nakayama H, Ito H, et al. Long-term outcomes after sublobar resection versus lobectomy in patients with clinical stage ⅠA lung adenocarcinoma meeting the node-negative criteria defined by high-resolution computed tomography and [¹⁸F]-fluoro-2-deoxy-d-glucose positron emission tomography[J]. Clin Lung CancerClin Lung Cancer, 2021, 22(3): e431-e437. doi: 10.1016/j.cllc.2020.06.013

[5]

陈学涛, 姚稚明. 术前¹⁸F-FDG PET/CT显像代谢参数在非小细胞肺癌患者预后评估中的应用进展[J]. 国际放射医学核医学杂志, 2020, 44(11): 704-708. doi: 10.3760/cma.j.cn121381-201908030-00090
Chen XT, Yao ZM. Application progress of preoperative ¹⁸F-FDG PET/CT imaging metabolic parameters in the prognostic evaluation of patients with non-small cell lung cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2020, 44(11): 704-708. doi: 10.3760/cma.j.cn121381-201908030-00090

[6]

Farsad M. FDG PET/CT in the staging of lung cancer[J]. Curr RadiopharmCurr Radiopharm, 2020, 13(3): 195-203-. doi: 10.2174/1874471013666191223153755

[7]

Gregory DL, Hicks RJ, Hogg A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data[J]. J Nucl MedJ Nucl Med, 2012, 53(7): 1007-1015. doi: 10.2967/jnumed.111.099713

[8]

Gkogkozotou VKI, Gkiozos IC, Charpidou AG, et al. PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness[J]. Lung Cancer ManagLung Cancer Manag, 2018, 7(2): LMT02-. doi: 10.2217/lmt-2018-0008

[9]

Ye B, Cheng M, Li W, et al. Predictive factors for lymph node metastasis in clinical stage ⅠA lung adenocarcinoma[J]. Ann Thorac SurgAnn Thorac Surg, 2014, 98(1): 217-223. doi: 10.1016/j.athoracsur.2014.03.005

[10]

Schimmer C, Neukam K, Elert O. Staging of non-small cell lung cancer: clinical value of positron emission tomography and mediastinoscopy[J]. Interact Cardiovasc Thorac SurgInteract Cardiovasc Thorac Surg, 2006, 5(4): 418-423. doi: 10.1510/icvts.2006.129478

[11]

Kagimoto A, Tsutani Y, Izaki Y, et al. Prediction of lymph node metastasis using semiquantitative evaluation of PET for lung adenocarcinoma[J]. Ann Thorac SurgAnn Thorac Surg, 2020, 110(3): 1036-1042. doi: 10.1016/j.athoracsur.2020.03.032

[12]

张毓艺, 姚稚明, 陈聪霞, 等. FDG PET/CT原发性代谢对非小细胞肺癌区域淋巴结转移预测价值[J]. 中华肿瘤防治杂志, 2018, 25(11): 816-820. doi: 10.16073/j.cnki.cjcpt.2018.11.013
Zhang YY, Yao ZM, Chen CX, et al. Value of metabolism by using FDG PET/CT of NSCLC primary tumor in prediction of lymph node metastasis[J]. Chin J Cancer Prev TreatChin J Cancer Prev Treat, 2018, 25(11): 816-820. doi: 10.16073/j.cnki.cjcpt.2018.11.013

[13]

Li SL, Zheng QF, Ma YY, et al. Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT[J/OL]. PLoS One, 2013, 8(10): e78552[2022-01-20]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078552. DOI: 10.1371/journal.pone.0078552.

[14]

张毓艺, 姚稚明, 薛倩倩, 等. ¹⁸F-FDG PET/CT鉴别诊断非小细胞肺癌患者不同密度肺门纵隔淋巴结良恶性的价值[J]. 中华核医学与分子影像杂志, 2020, 40(9): 513-517. doi: 10.3760/cma.j.cn321828-20190828-00183
Zhang YY, Yao ZM, Xue QQ, et al. Value of FDG PET/CT in the differential diagnosis of benign and malignant hilar mediastinal lymph nodes in patients with non-small cell lung cancer[J]. Chin J Nucl Med Mol ImagChin J Nucl Med Mol Imag, 2020, 40(9): 513-517. doi: 10.3760/cma.j.cn321828-20190828-00183

[15]

Betancourt-Cuellar SL, Carter BW, Palacio D, et al. Pitfalls and limitations in non-small cell lung cancer staging[J]. Semin RoentgenolSemin Roentgenol, 2015, 50(3): 175-182. doi: 10.1053/j.ro.2015.01.010

[16]

中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华医学杂志, 2021, 101(23): 1725-1757. doi: 10.3760/cma.j.cn112152-20210207-00118
Oncology Branch of Chinese Medical Association, Journal of Chinese Medical Association. Guidelines for clinical diagnosis and treatment of lung cancer, Chinese medical association oncology branch (2021 Edition)[J]. Chin Med JChin Med J, 2021, 101(23): 1725-1757. doi: 10.3760/cma.j.cn112152-20210207-00118

[17]

Chiappetta M, Meacci E, Nachira D, et al. Wedge resection, segmentectomy or lobectomy: the correct choice considering the risk of lobar lymph node involvement[J]. J Thorac DisJ Thorac Dis, 2019, 11(3): 618-620. doi: 10.21037/jtd.2019.02.87

[18]

Kagimoto A, Tsutani Y, Handa Y, et al. Patient selection of sublobar resection using visual evaluation of positron-emission tomography (PET) for early-stage lung adenocarcinoma[J]. Ann Surg OncolAnn Surg Oncol, 2021, 28(4): 2068-2075. doi: 10.1245/s10434-020-09150-w

[19]

Park SY, Cho A, Yu WS, et al. Prognostic value of total lesion glycolysis by ¹⁸F-FDG PET/CT in surgically resected stage ⅠA non-small cell lung cancer[J]. J Nucl MedJ Nucl Med, 2015, 56(1): 45-49. doi: 10.2967/jnumed.114.147561

[20]

Chou HP, Lin KH, Huang HK, et al. Prognostic value of positron emission tomography in resected stage ⅠA non-small cell lung cancer[J]. Eur RadiolEur Radiol, 2021, 31(10): 8021-8029. doi: 10.1007/s00330-021-07801-4

[21]

Koike T, Sato N, Hosoda Y, et al. Maximum standardized uptake value on positron emission tomography is associated with more advanced disease and high-risk features in lung adenocarcinoma[J]. Semin Thorac Cardiovasc SurgSemin Thorac Cardiovasc Surg, 2022, 34(3): 1051-1060. doi: 10.1053/j.semtcvs.2021.07.019

[22]

Park HL, Yoo IR, Boo SH, et al. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage ⅠA non-small cell lung cancer patients?[J]. J Cancer Res Clin OncolJ Cancer Res Clin Oncol, 2019, 145(4): 1021-1026. doi: 10.1007/s00432-019-02858-7

[23]

Furumoto H, Shimada Y, Imai K, et al. Prognostic impact of the integration of volumetric quantification of the solid part of the tumor on 3DCT and FDG-PET imaging in clinical stage ⅠA adenocarcinoma of the lung[J]. Lung CancerLung Cancer, 2018, 121: 91-96. doi: 10.1016/j.lungcan.2018.05.001

[24]

Tan HT, Ma MT, Huang J, et al. Glucose metabolism reprogramming of primary tumor and the liver is associated with disease-free survival in patients with early NSCLC[J/OL]. Front Oncol, 2021, 11: 752036[2022-01-20]. https://www.frontiersin.org/articles/10.3389/fonc.2021.752036/full. DOI: 10.3389/fonc.2021.752036.

[1]	Jacobs CD, Jafari ME. Early results of lung cancer screening and radiation dose assessment by low-dose CT at a community hospital[J]. Clin Lung CancerClin Lung Cancer, 2017, 18(5): e327-e331. doi: 10.1016/j.cllc.2017.01.011
[2]	陈英, 钟文昭. 第8版肺癌TNM分期浅析[J]. 临床外科杂志临床外科杂志, 2016, 24(7): 486-490. doi: 10.3969/j.issn.1005-6483.2016.07.002 Chen Y, Zhong WZ. Analysis of TNM staging of lung cancer in the 8th edition[J]. J Clin SurgJ Clin Surg, 2016, 24(7): 486-490. doi: 10.3969/j.issn.1005-6483.2016.07.002
[3]	Ye L, Xu F, Shi S, et al. A SUV_max-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage Ⅰ non-small cell lung cancer: unveiling the role of ¹⁸F-FDG PET/CT in clinical decision-making[J]. Clin Transl OncolClin Transl Oncol, 2018, 20(8): 1026-1034. doi: 10.1007/s12094-017-1819-7
[4]	Tsutani Y, Nakayama H, Ito H, et al. Long-term outcomes after sublobar resection versus lobectomy in patients with clinical stage ⅠA lung adenocarcinoma meeting the node-negative criteria defined by high-resolution computed tomography and [¹⁸F]-fluoro-2-deoxy-d-glucose positron emission tomography[J]. Clin Lung CancerClin Lung Cancer, 2021, 22(3): e431-e437. doi: 10.1016/j.cllc.2020.06.013
[5]	陈学涛, 姚稚明. 术前¹⁸F-FDG PET/CT显像代谢参数在非小细胞肺癌患者预后评估中的应用进展[J]. 国际放射医学核医学杂志国际放射医学核医学杂志, 2020, 44(11): 704-708. doi: 10.3760/cma.j.cn121381-201908030-00090 Chen XT, Yao ZM. Application progress of preoperative ¹⁸F-FDG PET/CT imaging metabolic parameters in the prognostic evaluation of patients with non-small cell lung cancer[J]. Int J Radiat Med Nucl MedInt J Radiat Med Nucl Med, 2020, 44(11): 704-708. doi: 10.3760/cma.j.cn121381-201908030-00090
[6]	Farsad M. FDG PET/CT in the staging of lung cancer[J]. Curr RadiopharmCurr Radiopharm, 2020, 13(3): 195-203-. doi: 10.2174/1874471013666191223153755
[7]	Gregory DL, Hicks RJ, Hogg A, et al. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data[J]. J Nucl MedJ Nucl Med, 2012, 53(7): 1007-1015. doi: 10.2967/jnumed.111.099713
[8]	Gkogkozotou VKI, Gkiozos IC, Charpidou AG, et al. PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness[J]. Lung Cancer ManagLung Cancer Manag, 2018, 7(2): LMT02-. doi: 10.2217/lmt-2018-0008
[9]	Ye B, Cheng M, Li W, et al. Predictive factors for lymph node metastasis in clinical stage ⅠA lung adenocarcinoma[J]. Ann Thorac SurgAnn Thorac Surg, 2014, 98(1): 217-223. doi: 10.1016/j.athoracsur.2014.03.005
[10]	Schimmer C, Neukam K, Elert O. Staging of non-small cell lung cancer: clinical value of positron emission tomography and mediastinoscopy[J]. Interact Cardiovasc Thorac SurgInteract Cardiovasc Thorac Surg, 2006, 5(4): 418-423. doi: 10.1510/icvts.2006.129478
[11]	Kagimoto A, Tsutani Y, Izaki Y, et al. Prediction of lymph node metastasis using semiquantitative evaluation of PET for lung adenocarcinoma[J]. Ann Thorac SurgAnn Thorac Surg, 2020, 110(3): 1036-1042. doi: 10.1016/j.athoracsur.2020.03.032
[12]	张毓艺, 姚稚明, 陈聪霞, 等. FDG PET/CT原发性代谢对非小细胞肺癌区域淋巴结转移预测价值[J]. 中华肿瘤防治杂志中华肿瘤防治杂志, 2018, 25(11): 816-820. doi: 10.16073/j.cnki.cjcpt.2018.11.013 Zhang YY, Yao ZM, Chen CX, et al. Value of metabolism by using FDG PET/CT of NSCLC primary tumor in prediction of lymph node metastasis[J]. Chin J Cancer Prev TreatChin J Cancer Prev Treat, 2018, 25(11): 816-820. doi: 10.16073/j.cnki.cjcpt.2018.11.013
[13]	Li SL, Zheng QF, Ma YY, et al. Implications of false negative and false positive diagnosis in lymph node staging of NSCLC by means of ¹⁸F-FDG PET/CT[J/OL]. PLoS One, 2013, 8(10): e78552[2022-01-20]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078552. DOI: 10.1371/journal.pone.0078552.
[14]	张毓艺, 姚稚明, 薛倩倩, 等. ¹⁸F-FDG PET/CT鉴别诊断非小细胞肺癌患者不同密度肺门纵隔淋巴结良恶性的价值[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2020, 40(9): 513-517. doi: 10.3760/cma.j.cn321828-20190828-00183 Zhang YY, Yao ZM, Xue QQ, et al. Value of FDG PET/CT in the differential diagnosis of benign and malignant hilar mediastinal lymph nodes in patients with non-small cell lung cancer[J]. Chin J Nucl Med Mol ImagChin J Nucl Med Mol Imag, 2020, 40(9): 513-517. doi: 10.3760/cma.j.cn321828-20190828-00183
[15]	Betancourt-Cuellar SL, Carter BW, Palacio D, et al. Pitfalls and limitations in non-small cell lung cancer staging[J]. Semin RoentgenolSemin Roentgenol, 2015, 50(3): 175-182. doi: 10.1053/j.ro.2015.01.010
[16]	中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华医学杂志中华医学杂志, 2021, 101(23): 1725-1757. doi: 10.3760/cma.j.cn112152-20210207-00118 Oncology Branch of Chinese Medical Association, Journal of Chinese Medical Association. Guidelines for clinical diagnosis and treatment of lung cancer, Chinese medical association oncology branch (2021 Edition)[J]. Chin Med JChin Med J, 2021, 101(23): 1725-1757. doi: 10.3760/cma.j.cn112152-20210207-00118
[17]	Chiappetta M, Meacci E, Nachira D, et al. Wedge resection, segmentectomy or lobectomy: the correct choice considering the risk of lobar lymph node involvement[J]. J Thorac DisJ Thorac Dis, 2019, 11(3): 618-620. doi: 10.21037/jtd.2019.02.87
[18]	Kagimoto A, Tsutani Y, Handa Y, et al. Patient selection of sublobar resection using visual evaluation of positron-emission tomography (PET) for early-stage lung adenocarcinoma[J]. Ann Surg OncolAnn Surg Oncol, 2021, 28(4): 2068-2075. doi: 10.1245/s10434-020-09150-w
[19]	Park SY, Cho A, Yu WS, et al. Prognostic value of total lesion glycolysis by ¹⁸F-FDG PET/CT in surgically resected stage ⅠA non-small cell lung cancer[J]. J Nucl MedJ Nucl Med, 2015, 56(1): 45-49. doi: 10.2967/jnumed.114.147561
[20]	Chou HP, Lin KH, Huang HK, et al. Prognostic value of positron emission tomography in resected stage ⅠA non-small cell lung cancer[J]. Eur RadiolEur Radiol, 2021, 31(10): 8021-8029. doi: 10.1007/s00330-021-07801-4
[21]	Koike T, Sato N, Hosoda Y, et al. Maximum standardized uptake value on positron emission tomography is associated with more advanced disease and high-risk features in lung adenocarcinoma[J]. Semin Thorac Cardiovasc SurgSemin Thorac Cardiovasc Surg, 2022, 34(3): 1051-1060. doi: 10.1053/j.semtcvs.2021.07.019
[22]	Park HL, Yoo IR, Boo SH, et al. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage ⅠA non-small cell lung cancer patients?[J]. J Cancer Res Clin OncolJ Cancer Res Clin Oncol, 2019, 145(4): 1021-1026. doi: 10.1007/s00432-019-02858-7
[23]	Furumoto H, Shimada Y, Imai K, et al. Prognostic impact of the integration of volumetric quantification of the solid part of the tumor on 3DCT and FDG-PET imaging in clinical stage ⅠA adenocarcinoma of the lung[J]. Lung CancerLung Cancer, 2018, 121: 91-96. doi: 10.1016/j.lungcan.2018.05.001
[24]	Tan HT, Ma MT, Huang J, et al. Glucose metabolism reprogramming of primary tumor and the liver is associated with disease-free survival in patients with early NSCLC[J/OL]. Front Oncol, 2021, 11: 752036[2022-01-20]. https://www.frontiersin.org/articles/10.3389/fonc.2021.752036/full. DOI: 10.3389/fonc.2021.752036.